Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-OX40 and Ipilimumab in Metastatic Melanoma
NCT01689870Phase 2Withdrawn
- Sponsor
- Ludwig Cancer Research
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of medi-6469 in melanoma, sponsored by Ludwig Cancer Research. Planned start Mar 2014; status: withdrawn.
02
Drugs
medi-6469
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01689870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01689870.